Drug information provided by: Merative, Micromedex®
Amivantamab-vmjw injection is used in combination with lazertinib as a first-line treatment for metastatic (cancer that has spread) or locally advanced (cannot be removed by surgery) non-small cell lung cancer (NSCLC) in patients who have an abnormal epidermal growth factor receptor (EGFR) gene (exon 19 deletions or exon 21 L858R substitution mutations). It is also used in combination with carboplatin and pemetrexed as a first-line treatment for metastatic or locally advanced NSCLC in patients who have an abnormal EGFR gene (exon 20 insertion mutations). This medicine is also used alone to treat metastatic or locally advanced NSCLC in patients who have an abnormal EGFR gene (exon 20 insertion mutations) and have received other cancer medicines (eg, platinum) but did not work well. Your doctor will perform a test before you take this medicine.
This medicine is to be given only by or under the supervision of your doctor.
This product is available in the following dosage forms:
Portions of this document last updated: Sept. 01, 2024
Copyright: © Merative US L.P. 1973, 2024. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.
妙佑医疗国际不为任何公司或产品背书。广告收入为我们的非营利使命提供支持。
浏览妙佑医疗国际出版社提供的畅销书以及书籍和简报的特别优惠。
您的捐赠可以抵税。请您慷慨解囊,和我们一起进行尖端研究和医护,共同推动医学的改变。